Advicenne's ADV7103 receives Orphan Drug Designation from the FDA for cystinuria treatment.

Advicenne's ADV7103 receives Orphan Drug Designation from the FDA for treating cystinuria, a hereditary kidney disorder affecting 30,000 US patients. This designation follows the previous granting of ODD status for ADV7103 in distal Renal Tubular Acidosis (dRTA) in December 2022. Advicenne, a specialty pharmaceutical company, now plans to partner for the drug's development and marketing in the US.